Southern Federal University, Academy of Biology and Biotechnology, Department of Genetics, Human and Animal Genetics laboratory, 194/1 Stachki Ave, Rostov-on-Don, Russia 344090.
Curr Res Transl Med. 2023 Apr-Jun;71(2):103379. doi: 10.1016/j.retram.2023.103379. Epub 2023 Jan 25.
Children with acute myeloid leukemia (AML) face a relapse of the disease in 30% of all cases. AML relapse is difficult to predict, and existing risk scales are often ineffective. Using data from the Therapeutically Applicable Research to Generate Effective Treatments (TARGET-AML) project, we defined an expression signature based on matrix RNAs (mRNAs) and long non-coding RNAs (lncRNAs) that could predict relapse in pediatric AML patients. We used a comprehensive bioinformatics analysis that included the identification of functionally significant differentially expressed genes in AML relapse, several rounds of association with relapse-free survival (RFS) mRNAs and lncRNAs selection, and evaluation of the obtained expression signatures to predict recurrence at the primary tumor level. Two mRNAs (ENSG00000149289.11 (ZC3H12C) and ENSG00000075213.11 (SEMA3A)) and one lncRNA (ENSG00000287569.1) were associated with a decreased RFS. Models including changes in the expression of ZC3H12C and ENSG00000287569.1, as well as all three markers, demonstrated very good quality and could predict the recurrence of pediatric AML.
约 30%的儿童急性髓系白血病（AML）患者会出现疾病复发。AML 复发难以预测，且现有的风险评分通常无效。我们利用 Therapeutically Applicable Research to Generate Effective Treatments (TARGET-AML) 项目的数据，基于矩阵 RNA（mRNA）和长非编码 RNA（lncRNA）定义了一个可预测儿科 AML 患者复发的表达特征。我们采用了一种全面的生物信息学分析方法，包括确定 AML 复发中具有功能意义的差异表达基因，与无复发生存（RFS）mRNA 和 lncRNA 选择进行几轮关联，以及评估获得的表达特征以预测原发性肿瘤水平的复发。两个 mRNA（ENSG00000149289.11（ZC3H12C）和 ENSG00000075213.11（SEMA3A））和一个 lncRNA（ENSG00000287569.1）与 RFS 降低相关。包含 ZC3H12C 和 ENSG0287569.1 表达变化的模型，以及所有三个标志物的模型，均表现出非常好的质量，可预测儿科 AML 的复发。
